Roche Holding AG, a Swiss-based company established in Basel in 1896, stands as a major global entity in both the pharmaceutical and diagnostic sectors. Its operations are widespread, covering nations such as Switzerland, Germany, the United States, the United Kingdom, France, Belgium, and many others internationally. The company's pharmaceutical division concentrates on developing and providing a diverse array of medications for critical health conditions. These include treatments for oncology, neuroscience, infectious diseases, immunology, cardiovascular and metabolic disorders, ophthalmology, and respiratory ailments. Additionally, it addresses needs related to anemia, various cancers, dermatology, hemophilia, inflammatory and autoimmune conditions, neurological issues, and transplantation. In parallel, Roche's diagnostics segment offers an extensive portfolio of in vitro tests designed for the identification of numerous diseases like cancer, diabetes, COVID-19, hepatitis, and human papillomavirus. This segment also delivers essential diagnostic instruments and chemical reagents. Furthermore, Roche is collaborating with Synlogic, Inc. on a research initiative to uncover a novel synthetic biotic treatment for inflammatory bowel disease (IBD).
